The 6 W’s: Who, what, where, when, why and what of it… Read more…
A new stem cell “skin gun” is being developed Read more…
Life sciences venture capital (VC) investment fell steeply during Q4/10, Read more…
Scientists at UCLA have developed what they claim is a fully chemically defined, animal-free alternative to standard mouse feeder cell-and bovine sera-containing culture systems for human embryonic stem cells (hESCs). Read more…
RENE will place 181.3M shares in 3 separate tranches at a price of 5.5 pence, a 17% discount to the closing price on 12/10/10 of 6.6 pence raising £10M from investors. Read more…
Vascular endothelial cells which line blood vessels with the ability to generate bone, cartilage and fat cells have been transformed into stem-like cells Read more…
Regeneron/Bayer’s VEGF Trap-Eye versus Genentech’s Ranibizumab … and Avastin versus Advanced Cell Technology’s stem cell therapy. Read more…
Adding to our Report Card blog of 11/15/10: Read more…
ASTM’s shares rose to 1.91 (7.30%) beyond (10:30 am) the opening. Read more…
ASTM has granted fast track designation for their critical limb ischemia (CLI) cell therapy development program. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.